CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 9 enrolled
Drug / intervention
Buprenorphinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02187198
NCT02187198Phase 3Completed
CompareCT.gov

Buprenorphine Treatment for Prescription Opioid Dependence

Yale University·interventional·Posted Jul 10, 2014·Updated Mar 10, 2023

In Brief

A Phase 3 clinical trial evaluating Buprenorphine for Opioid Dependence. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX tablet in low dose range (less than or equal to 8/2mg) vs. high dose range (greater than or equal to 16, range 16-24mg). The main outcomes of interest will be treatment retention, use of opioids, and the use of other drugs of abuse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Dependence
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 10, 2014
Enrollment StartMar 1, 2015
Primary CompletionFeb 1, 2022
Study CompletionJan 1, 2023
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 12.0 years ago

Interventions

Buprenorphinedrug